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http:WHAT THIS PAPER ADDS
Minimally invasive interventional procedures tend to be even less invasive. In this spirit, 4F sheath compatible
femoropopliteal stents have been developed. The number of studies regarding the safety, clinical outcome, and
fracture rate of 4F stents is limited. Access site complications occurred in 2% of the patients. The overall primary
patency rate was 80% with 85% freedom from target lesion revascularization at 12 months. The incidence of
stent fractures was 26% after an average follow up of 25 months. These results conﬁrm the validity of 4F stents
in patients with femoropopliteal occlusive disease.Objective: To determine the safety, clinical outcome, and fracture rate of femoropopliteal interventions using 4F
stents.
Methods: Between January 2010 and December 2011, 112 symptomatic patients were treated by stent
implantation. Ten patients were lost to follow up; therefore, 102 patients (62 men; mean age 66.4  10.1 years)
were retrospectively analyzed. The indication for femoropopliteal revascularization was severe claudication
(RutherfordeBecker score ¼ 3) in 63 (62%) patients and chronic critical limb ischemia (RutherfordeBecker
score ¼ 4e6) in 39 (38%). Follow up included palpation of peripheral pulses and measurement of ankle brachial
index. In patients with suspected in-stent restenosis duplex ultrasonography was performed. In 2013, patients
were asked to return for a ﬂuoroscopic examination of the stents.
Results: 114 lesions (Trans-Atlantic InterSociety Consensus-C and D, n ¼ 45) were treated with 119 stents (Astron
Pulsar, n ¼ 42; Pulsar-18, n ¼ 77). Lesions were long (100 mm) in 49 cases and heavily calciﬁed in 35. Stents
were long (120 mm) in 46 cases. Ten stents were partially overlapped. The technical and clinical success rates
were 100%. Two puncture related complications were noted, neither of which required surgical repair. Eleven
patients died (myocardial infarction, n ¼ 4; stroke, n ¼ 2; cancer, n ¼ 5) and nine patients underwent major
amputation (above knee, n ¼ 4). The primary patency rate was 83% at 6 months and 80% at 12 months. The
primary assisted patency rate was 97% at 6 months and 94% at 12 months. The secondary patency rate was 86%
at 6 months and 85% at 12 months. The prevalence of fractures was 26% (type III and IV, 10%) after an average
follow up of 25 months.
Conclusion: Femoropopliteal stenting using a 4F compatible delivery system can be accomplished with a low
complication rate, acceptable fracture rate, and with similar 12 month patency and revascularization rates as
their 6F counterparts.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Nowadays, femoropopliteal interventions are one of the
most commonly performed endovascular procedures. If the
stenosis is suitable for endosurgery, percutaneous trans-
luminal angioplasty (PTA) should be the treatment of ﬁrstrresponding author.
il address: dosaedit@yahoo.com (E. Dósa).
-5884/ 2014 European Society for Vascular Surgery. Published by
r Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2014.12.004choice. Stent placement is reserved for patients with unfa-
vorable lesion morphology (heavily calciﬁed lesions, total
occlusions) and suboptimal PTA results (residual stenosis
30%, ﬂow limiting dissection). Over the years, signiﬁcant
changes in the structure and design of vascular stents to
improve their radial force, ﬂexibility, and fracture resistance
have been made. However, until a few years ago, femo-
ropopliteal stenting has been performed using 6F sheaths.
Recently, self expanding stents that are compatible with 4F
delivery devices have become available. However, with the
exception of the 4-EVER (4F Endovascular Treatment
Approach to Infrainguinal Disease) and PEACE I (Patency
200 H. Sarkadi et al.Evaluation After Implantation of the Pulsar-18 Self-Expand-
ing Nitinol Stent in the Superﬁcial Femoral and Popliteal
Arteries) trials,1,2 no comprehensive data have been pub-
lished on 4F stents in patients with femoropopliteal disease.
Therefore, the aim of this retrospective study was to
determine the safety, clinical outcome, and fracture rate of
femoropopliteal stenting using a 4F compatible delivery
system.PATIENTS AND METHODS
Patient selection
The number of patients having any form of endovascular
intervention to the femoropopliteal segment between
January 2010 and December 2011 was 441. In this retro-
spective study only those 112 consecutive patients with
severe claudication (RutherfordeBecker score ¼ 3) or
chronic critical limb ischemia (CLI; Rutherford-Becker
score ¼ 4e6) who underwent femoropopliteal stenting
using a 4F compatible delivery system were analyzed.3 The
indication for stent placement was suboptimal PTA due to
unfavorable lesion morphology (heavily calciﬁed lesions,
total occlusions) or failed angioplasty (residual stenosis
30%, ﬂow limiting dissection). The procedures were per-
formed at the Heart and Vascular Center and at the
Department of Radiology and Oncotherapy of the Sem-
melweis University (Budapest, Hungary).Stenting protocol
The pre-procedural work up included collection of clinical
data (symptoms, risk factors, medical history), palpation of
femoropopliteal and foot pulses, measurement of ankle
brachial index (ABI), and assessment of lower extremity
arterial disease with duplex ultrasonography or computed
tomography angiography.
The procedures were carried out through the femoral
artery, via an ipsilateral antegrade approach in 79 cases and
via a contralateral crossover approach in 31. In two patients
an ipsilateral retrograde approach was necessary (one
through the popliteal artery [PA] and one through the
dorsalis pedis artery) because of failed recanalization
through the femoral artery. A 4F introducer sheath was
used in all cases.
After selective angiography, a 0.035 inch or 0.018 inch
guidewire was advanced into the punctured artery to pass
through the femoropopliteal stenosis or occlusion. Lesions
were classiﬁed according to the Trans-Atlantic InterSociety
Consensus (TASC II) document.4 Beside the TASC classiﬁ-
cation, lesions were considered long if their length was
100 mm, and were deﬁned as heavily calciﬁed if calciﬁ-
cation was visible over >75% of the length of the stenotic
or occluded segment by ﬂuoroscopy.
The diameter of the patent segment and length of the
lesion were measured on baseline angiograms for accurate
sizing of the balloons and stents. The angioplasty balloons
were Passeo-18 (4e6  40e200 mm; Biotronik AG, Bülach,
Switzerland) in 82 patients and Fox SV (5e6  40e120 mm;Abbott Vascular Inc., Santa Clara, CA, USA) in 32. Self-
expanding nitinol stents (Astron Pulsar, n ¼ 42; Pulsar-18,
n ¼ 77 [Biotronik AG]) were implanted in all cases. Stents
were considered long if their length was 120 mm. At the
end of the procedure completion angiography was per-
formed, the punctured artery was compressed manually,
and an overnight pressure bandage was then applied. Pa-
tients were discharged 1e2 days after the procedure.
Technical success was deﬁned as <30% residual stenosis
without dissection or extravasation, whereas clinical success
meant improvement or resolution of the symptoms.Follow up
Follow up visits were scheduled at 4 weeks, 3e6, and 12
months after stenting and annually thereafter. Follow up
examinations included evaluation of symptoms, palpation
of femoropopliteal and foot pulses, and measurement of
ABI. In patients with worsened symptoms, impalpable
popliteal pulse, and ABI 0.5 signiﬁcant in-stent restenosis
(ISR) was suspected. The presence of ISR was veriﬁed with
duplex ultrasonography.
Patency rates were expressed as primary (those remain-
ing patent without further intervention), primary assisted
(those patent with additional intervention to maintain
patency), and secondary (those in which patency needed to
be re-established by another intervention).5 Target lesion
revascularization was deﬁned as any repeat percutaneous
intervention of the target lesions (including 5 mm proximal
and distal to the stent) or surgical bypass of the target
vessel performed for restenosis or other complication
involving the target lesion, whereas target vessel revascu-
larization meant any repeat percutaneous intervention or
surgical bypass of any segment of the target vessel.6
In 2013, patients were asked to return for an additional
follow up visit, when ﬂuoroscopic stent fracture evaluation
was also performed in addition to the above mentioned
examinations. The high magniﬁcation ﬂuoroscopic exami-
nations were done in the angiography suite (AXIOM Artis
FA; Siemens Medical Solutions AG Corp., Erlangen, Ger-
many) with the following parameters: 7.5 fps, 100e125 kV,
and 550e800 mA (Heart and Vascular Center); or in an
examination room equipped with an X-ray system using a
digital ﬂat panel (Carestream DRX-1 System; Carestream
Health Inc., Rochester, NY, USA) with the following param-
eters: 60e70 kV, 63 mA with grid (Department of Radiology
and Oncotherapy). To visualize the implanted stents, three
cine loops with a length of three cardiac cycles (Heart and
Vascular Center) or digital X-rays (Department of Radiology
and Oncotherapy) were recorded in postero-anterior, and
right and left anterior oblique 30e45 projections. The post-
processing was performed on a Leonardo Workstation
(Syngo 2003; Siemens Medical Solutions) (Heart and
Vascular Center) or on a PACS Workstation (IMPAX 6.5.2;
Agfa HealthCare NV Corp., Mortsel, Belgium) (Department
of Radiology and Oncotherapy). The ﬂuoroscopic images
were analyzed by two experienced interventional radiolo-
gists (E.D., B.N.) in consensus. Stent fractures were deﬁned
Table 1. Lesion characteristics.




Grade of stenosis (%), mean  SD 91.5  8.8
Total occlusion 50 (44)
Length (mm), mean  SD 80.9  64.1
Length 100 mm 49 (43)
Calciﬁcation 57 (50)
Heavy calciﬁcation 35 (31)
Location
Left side 58 (51)
Results of Femoropopliteal Stenting Through 4F Sheaths 201according to a nitinol stent fracture classiﬁcation that has
been proposed by the Cardiovascular Institute of the South
(Houma, LA, USA).7 Brieﬂy, type I ¼ single strut fracture,
type II ¼ multiple strut fractures at different locations in
the stent, type III ¼ multiple strut fractures resulting in
complete transverse fracture of the stent, and type
IV ¼ complete transverse fracture with subsequent stent
separation. The ﬂuoroscopic examination of the implanted
stents was conducted in accordance with the Declaration of
Helsinki. This study was approved by the ethics committee
of the Semmelweis University and informed consent was
obtained from every patient.Right side 56 (49)
Proximal SFA 2 (2)
Proximal-mid SFA 6 (5)
Mid SFA 7 (6)
Mid-distal SFA 6 (5)
Distal SFA 7 (6)
Entire SFA 8 (7)
Femoropopliteal transitional zone 47 (41)
P1-2 segments 15 (13)






Note. Values are given as n (%) unless otherwise indicated.
SFA ¼ Superﬁcial femoral artery; TASC ¼ Trans-Atlantic
InterSociety Consensus.Statistical analysis
Statistical analysis was performed with SPSS 21.0 software
(IBM, Armonk, NY, USA). Categorical variables were
expressed as numbers and percentages, and were
compared between two groups using the chi-square test or
the Fisher’s exact test. Continuous variables were expressed
as means  SDs and were compared between two groups
using the Student t test or the ManneWhitney U test. The
patency rates were analyzed using the KaplaneMeier
technique. Univariate logistic regression model was used to
identify independent predictors of ISR and stent fracture.
All analyses were two tailed, and values of p  .05 were
considered to be statistically signiﬁcant.
RESULTS
Patient data
Ten patients were lost to follow up; therefore, they were
excluded from the analysis. The mean age of the remaining
102 patients (40 women, 62 men) was 66.4  10.1 years
(range 39e87 years). The indication for femoropopliteal
revascularization was severe claudication in 63 (62%)
patients and chronic CLI in 39 (38%). At the time of inter-
vention, none of the patients had signiﬁcant ipsilateral iliac
or common femoral artery stenosis. Atherosclerotic risk
factors included smoking in 89 (87%) patients, hypertension
in 96 (94%), hyperlipidemia in 41 (40%), diabetes mellitus
in 42 (41%), obesity in 44 (43%), and chronic kidney disease
in 16 (16%). According to the medical history, 27 (26%)
patients had coronary artery bypass grafting and/or
percutaneous coronary intervention, 23 (23%) had supra-
aortic surgical and/or endosurgical reconstruction, and 21
(21%) had lower extremity open and/or percutaneous
revascularization.Table 2. Stent characteristics.
Variables Stents (n ¼ 119)
Type
4F Astron Pulsar 42 (35)
4F Pulsar-18 77 (65)
Length (mm), mean  SD 92.2  53.0
Length 120 mm 46 (39)
Overlapping stents 10 (8)
Note. Values are given as n (%) unless otherwise indicated.Lesion and stent characteristics
One hundred and fourteen lesions were treated with 119
stents. The stented lesions were de novo stenosis in 87
(76%) cases and recurrent stenosis after previous PTA in 27
(24%). Sixty four (56%) of the treated lesions were stenoses
and 50 (44%) were total occlusions. Lesions were long in 49
(43%) cases and heavily calciﬁed in 35 (31%). The side dis-
tribution of the lesions was almost equal (left, n ¼ 58; right,
n ¼ 56). Lesions were located in the superﬁcial femoralartery (SFA) in 36 (32%) cases, in the femoropopliteal
transitional zone in 47 (41%), and in the PA in 31 (27%). In
17 (15%) patients crural interventions were also performed.
According to the TASC classiﬁcation, the lesions were TASC-
A, TASC-B, TASC-C, and TASC-D in 35 (31%), 34 (30%), 30
(26%), and 15 (13%) cases, respectively (Table 1). Forty six
(39%) of the implanted stents were long and 10 (8%) stents
were placed in a partially overlapping position (Table 2).
Early post-procedural period (within 30 days)
The technical success rate was 100%. A femoral pseudoa-
neurysm developed at the femoral puncture site in two
patients; both of them were treated with ultrasound guided
injection of thrombin. The 30 day all cause mortality rate
was zero. Five (5%) patients underwent minor amputation
(interphalangeal, n ¼ 2; ray, n ¼ 2; transmetatarsal, n ¼ 1).
All patients reported improvement or resolution of the pre-
procedural symptoms.
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Themean follow up timewas 25.3 6.2months (range 3e39
months). Eleven (11%) patients died during the follow up
period (acute myocardial infarction, n ¼ 4; stroke, n ¼ 2;
cancer, n ¼ 5). Signiﬁcant ISR was observed in 21 (21%) pa-
tients. Target lesion revascularization was carried out in 15
(15%) patients (PTA, n ¼ 13; stenting, n ¼ 2), while target
vessel revascularization was carried out in six (6%) patients
(PTA, n ¼ 3; stenting, n ¼ 1; surgery, n ¼ 2). Major ampu-
tationwas necessary in nine (9%) patients (below knee, n¼ 5;
above knee, n ¼ 4). Indications for amputation were acute
ischemia in four cases and chronic ischemia in ﬁve. All stents
were patent in the below knee amputation group, while all
stents were blocked in the above knee amputation group.The
primary patency rate was 83% at 6 months and 80% at 12
months. The primary assisted patency rate was 97% at 6
months and 94% at 12 months. The secondary patency rate
was 86%at 6months and 85%at 12months (Fig. 1).Themean
resting ABI improved from 0.5 0.1 before the procedure to
0.8  0.2 at the most recent follow up (p < .01). The mean
RutherfordeBecker classiﬁcation improved from 3.9  1.1
before the procedure to 2.1  1.4 at the most recent follow
up (p < .01).Figure 1. (A) Primary, (B) primary assisteStent fracture
Patients who died or underwent above knee amputation
and who had stents that were placed during the follow up
were excluded from the analysis of stent fractures. One
hundred and four stents were examined. Twenty seven
(26%) fractures were detected in 87 patients: fractures were
type I in nine, type II in eight, type III in ﬁve, and type IV in
ﬁve cases. Eighty three percent of the fractures were pre-
dominantly in the middle portion of the stents. At the time
of the ﬂuoroscopic investigation, the number of patients
with ISR (occurring at any time during the follow up) was
signiﬁcantly higher in the fractured than in the non-
fractured group (n ¼ 15 vs. n ¼ 2; p < .01).
Predictors of ISR and stent fracture
The following variables were examined: female sex, age
70 years, smoking, hypertension, hyperlipidemia, diabetes
mellitus, obesity, chronic kidney disease, total occlusion,
long lesion, calciﬁed lesion, heavily calciﬁed lesion, TASC-A
lesion, TASC-B lesion, TASC-C lesion, TASC-D lesion, prox-
imal SFA stent, proximal-mid SFA stent, mid SFA stent, mid-
distal SFA stent, distal SFA stent, femoropopliteal transi-
tional zone stent, P1-2 stent, P1-3 or P2-3 stent, long stent,d, and (C) secondary patency rates.
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Univariate analysis showed that stents placed in P1-2
location are associated with an increased incidence of
ISR (odds ratio [OR] 3.83, 95% conﬁdence interval [CI]
1.10e13.31, p ¼ .03). Calciﬁed, especially heavily calciﬁed
lesions were found to be predictive of stent fracture (OR
19.64, 95% CI 4.31e89.47, p < .01; OR 116.07, 95% CI
22.57e597.03, p < .01, respectively).DISCUSSION
Access site complications were found in 2% of the patients.
At 12 months, there was an 80% overall primary patency
rate and 85% freedom from target lesion revascularization.
The incidence of stent fractures was 26% (after an average
follow up of 25 months).
The number of peripheral vascular interventions is
increasing annually. Besides major complications, there are
additional arterial puncture related complications, such as
hematoma, bleeding, arteriovenous ﬁstula, pseudoaneur-
ysm, arterial occlusion, femoral neuropathy, and infection,
which, in turn, are associated with increased morbidity,
mortality, and cost.8,9 Increased sheath size increases the
risk of access site complications.9 Up until a few years ago,
femoropopliteal stenting was performed using 6F sheaths.
The reported incidence of puncture site complications
during interventions through 6F sheaths varies between
studies, but could be as high as 20%,9 depending on the
deﬁnition and criteria used. Recently, self expanding fem-
oropopliteal stents that are deliverable through 4F sheaths
have been introduced. Two large prospective multicenter
trials (4-EVER and PEACE I) have been carried out to
examine the safety and efﬁcacy of implantation of 4F stents
in patients with symptomatic femoropopliteal occlusive
disease.1,2 The access related complication rates were 3.3%
in the 4-EVER trial and 2.0% in the current study, and all of
the complications could be managed by non-surgical
treatments.1 These rates are lower than most of the pub-
lished rates on 6F devices.9
Regarding efﬁcacy of the procedures, the overall 12
month primary patency rate was 81.4% in the 4-EVER trial,
79.5% in the PEACE I trial, and 80.0% in the current study,
while the freedom from target lesion revascularization at 12
months was 89.3%, 81.0%, and 85.0%, respectively.1,2 The
slightly worse results in the PEACE I trial can be explained
by the fact that the percentage of patients with TASC-D
lesions and total occlusions was higher (32.2% and 56.7%,
respectively) compared with the 4-EVER trial (0% and
20.8%, respectively) and the current study (13.0% and
44.0%, respectively).1,2 Moreover, the treated lesions were
longer in the PEACE I trial (111.5  71.4 mm) than they
were in the 4-EVER trial (71.0  45.9 mm) and the current
study (80.9  64.1 mm).1,2 Two other smaller 4F studies
should be mentioned; in one of them only patients with
TASC-D lesions were enrolled, while only those having long
segment femoropopliteal stenosis (120 mm) were
enrolled in the other.10,11 The 12 month patency and
revascularization rates of these two studies are similar tothe rates of the PEACE I trial.2,10,11 More importantly, these
results are not worse than the reported 12 month outcomes
of the 6F stents.12e18
Neointimal hyperplasia is the major cause of ISR. Patient
speciﬁc characteristics (e.g., ubiquitous comorbidities,
insufﬁcient antiplatelet therapy), as well as many lesion,
stent, and procedure related factors (e.g., stent type, stent
design, stent conﬁguration, stent diameter, stent length,
incomplete stent apposition, incomplete stent expansion,
overlapping stents) are known to precipitate ISR.19 Femo-
ropopliteal ISR occurs with a frequency of 19e37% at 12
months in lesions that are <150 mm in length.14,20 In the
current study, the incidence of ISR was 21% and stents in
P1-2 location were found to be associated with ISR. Early
and Kelly have shown that certain dynamic forces, such as
bending the artery during knee ﬂexion, cause permanent
deformation of the stent, which negatively affects the
dynamics of blood ﬂow in the vessel and contributes to
ISR.21
Stent fractures have been extensively investigated in
many vascular territories and were noted to be one of the
most common in the femoropopliteal arteries, with a
prevalence of 2e65%.22 Here, a 26% fracture rate was re-
ported after an average follow up of 25 months. A literature
search for the fracture rates of 4F Astron Pulsar and Pulsar-
18 stents revealed only one study (the 4-EVER trial).1
Although, the fracture rate was 4.2% in this trial, the per-
centage of patients with TASC-D lesions, total occlusions,
calciﬁed lesions, and long stents was signiﬁcantly lower
compared with the current study.1 Femoropopliteal stents
are almost continuously exposed to mechanical forces,
which can themselves result in “stress” fractures, especially
when stents are placed behind the knee. Patient, lesion,
stent, and procedure related parameters may further in-
crease the risk of fracture.23 Calciﬁed lesions were found to
be predictive of fracture in the current study. Calciﬁcation
due to changes in the regional wall stiffness and creating
excessive focal pressure on certain parts of the stent has
already been demonstrated to play a role in the develop-
ment of stent fracture.22Conclusion
Femoropopliteal stenting using a 4F sheath compatible
delivery system can be accomplished with few puncture site
complications and similar 12 month patency and revascu-
larization rates as their 6F counterparts. The early results
are promising, even if stent fractures are common, espe-
cially in patients with calciﬁed lesions. But the more
important long-term outcomes are still awaited.CONFLICT OF INTEREST
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